Peroneal mononeuropathy in pediatric Hodgkin's disease.
A 12-year-old boy with Hodgkin's disease developed left peroneal nerve palsy during combination therapy with chemotherapy and low-dose irradiation. The palsy occurred twice; around 1-2 weeks after the second administration of vincristine in the second and third COPP (cyclophosphamide, vincristine, prednisolone, and procarbazine) regimens. Without any treatment, the peroneal neuropathy completely resolved clinically three months and electromyographically six months after the onset. He used to play television games for more than 6 hours a day with the legs crossed while sitting on the bedside. Compared to adult patients, little is known about the relationship between peroneal neuropathy and systemic malignant diseases in pediatric patients. This case shows for the first time that habitual leg crossing during potentially neurotoxic chemotherapy could induce peroneal mononeuropathy in a pediatric cancer patient.
Matsubara
K
K
Department of Pediatrics, Nishi-Kobe Medical Center, Kobe, Japan. kskmatsu@portnet.ne.jp
Nigami
H
H
Harigaya
H
H
Osaki
M
M
Baba
K
K
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects; D002648:Child; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D006689:Hodgkin Disease / Q000150:complications / Q000188:drug therapy* / Q000532:radiotherapy; D006801:Humans; D008297:Male; D020422:Mononeuropathies / Q000139:chemically induced* / Q000209:etiology; D020427:Peroneal Neuropathies / Q000139:chemically induced* / Q000209:etiology; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects; D011344:Procarbazine / Q000008:administration & dosage / Q000009:adverse effects; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
D011344:Procarbazine; D014750:Vincristine; D003520:Cyclophosphamide; D011241:Prednisone